Conv. Plasma
Nigella Sativa

All colchicine studies
Meta analysis
study COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 12% primary Improvement Relative Risk Death/intubation 17% primary Death/intubation (b) 52% Mortality (b) 17% Death/intubation (c) 25% Colchicine  Diaz et al.  LATE TREATMENT  RCT Is late treatment with colchicine beneficial for COVID-19? RCT 1,279 patients in Argentina (April 2020 - March 2021) Lower mortality (p=0.3) and death/intubation (p=0.08), not sig. Diaz et al., JAMA Network Open, December 2021 Favors colchicine Favors control

Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19

Diaz et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.41328, NCT04328480
Dec 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Very late stage RCT (O2 88%, 84% on oxygen) with 1,279 hospitalized patients in Argentina, showing lower mortality and lower combined mortality/ventilation, statistically significant only for the combined outcome and per-protocol analysis. NCT04328480 (history). COLCOVID.
This study is excluded in the after exclusion results of meta analysis: very late stage, oxygen saturation <90% at baseline; very late stage, >80% on oxygen/ventilation at baseline.
risk of death, 12.0% lower, HR 0.88, p = 0.30, treatment 131 of 640 (20.5%), control 142 of 639 (22.2%), NNT 57, adjusted per study, Cox proportional hazards, primary outcome.
risk of death/intubation, 17.0% lower, HR 0.83, p = 0.08, treatment 160 of 640 (25.0%), control 184 of 639 (28.8%), NNT 26, adjusted per study, Cox proportional hazards, primary outcome.
risk of death/intubation, 52.0% lower, HR 0.48, p = 0.60, treatment 6 of 93 (6.5%), control 13 of 102 (12.7%), NNT 16, adjusted per study, subset not on supplemental oxygen, Cox proportional hazards.
risk of death, 17.0% lower, HR 0.83, p = 0.30, treatment 98 of 515 (19.0%), control 140 of 634 (22.1%), NNT 33, adjusted per study, PP, Cox proportional hazards.
risk of death/intubation, 25.0% lower, HR 0.75, p = 0.02, treatment 117 of 515 (22.7%), control 181 of 634 (28.5%), NNT 17, adjusted per study, PP, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Diaz et al., 29 Dec 2021, Randomized Controlled Trial, Argentina, peer-reviewed, 101 authors, study period 17 April, 2020 - 28 March, 2021, dosage 2mg day 1, 1mg days 2-14, trial NCT04328480 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19
MD Rafael Diaz, MD Andrés Orlandini, MSc Noelia Castellana, MD Alberto Caccavo, MD Pablo Corral, MD Gonzalo Corral, MD Carolina Chacón, MD Pablo Lamelas, MD; María Fernando Botto, María Luz Díaz, MD Juan Manuel Domínguez, Andrea Pascual, Carla Rovito, MD; Agustina Galatte, MSc, MD Franco Scarafia, MD Omar Sued, MD Omar Gutierrez, PhD Sanjit S Jolly, PhD; José M Miró, MBBS John Eikelboom, MSc Mark Loeb, MD, MSc Aldo Pietro Maggioni, MD, MPH Deepak L Bhatt, MD, MPH Salim Yusuf, Lorena Lopez, Juan Muntaner, Antonela Bobato, MD Gonzalo Corral, Gustavo Benavent, Diego Espinel, Sandra M Del Valle Almagro, Eleonora E Montenegro, Adrian Núñez, Lisandro Pérez Valega, Martin Christin, Leda Guzzi, Gabriela Finelli, Lilina B Schiavi, Eduardo Ferro Queirel, Luis M Moltrasio, Horacio A Fermín, Jorge V Martínez, Omar Gutiérrez, Eleonora Cunto, Pablo A Saúl, María Del Pilar Cabrera Maciel, Javier Muntaner, Damián Lerman, Paula I Truccolo, Adrián Armano, Esther V Jalife, Romina M Bertuzzi, María Inés Jean Charles, Pablo A Fernandez, MD Alberto Caccavo, Nicolás Vittal, Lucia Lampone Tappata, Diego M Murizzi, Brenda L Fernandez, Antonio Montes De Oca, Guadalupe Diaz Vega, Felipe N Queti, Luis A Calafell, Mariano Sequeira, Ricardo León De La Fuente, Julio Núñez Burgos, Sonia Del Valle Armaraz, Patricia Flores, Mariana Bellanting, Narela Blazevich, Baltasar Finucci Curi, Romina P Cabrini, Martín E Langone, Álvaro E Figueroa, Maria T Iglesias, Maria Carolina Alvero, Cesar G Lemir, José Bonorino, María Laura Pereyra, Ezequiel Barral, Mariela Rasmussen, María F Daglio, Mariano D Estofan, Francisco M Perea, Sebastián E Duhalde, María Fernanda Motta, Ignacio Romero, Guillermo Isa Massa, Celso F García, Rubén García Durán, Elena Cornejo Pucci, Silvia Saavedra, Carolina Bozikovich, Luciano Lovesio, María J Fernandez Moutin, Cristian C G Forciniti, Hugo Colombo, Nicolas Sabas, Leonardo Pilón, Adriana P Steren
JAMA Network Open, doi:10.1001/jamanetworkopen.2021.41328
IMPORTANCE Hospitalized patients with COVID-19 pneumonia have high rates of morbidity and mortality. OBJECTIVE To assess the efficacy of colchicine in hospitalized patients with COVID-19 pneumonia. DESIGN, SETTING, AND PARTICIPANTS The Estudios Clínicos Latino América (ECLA) Population Health Research Institute (PHRI) COLCOVID trial was a multicenter, open-label, randomized clinical trial performed from April 17, 2020, to March 28, 2021, in adults with confirmed or suspected SARS-CoV-2 infection followed for up to 28 days. Participants received colchicine vs usual care if they were hospitalized with COVID-19 symptoms and had severe acute respiratory syndrome or oxygen desaturation. The main exclusion criteria were clear indications or contraindications for colchicine, chronic kidney disease, and negative results on a reverse transcription-polymerase chain reaction test for SARS-CoV-2 before randomization. Data were analyzed from June 20 to July 25, 2021. INTERVENTIONS Patients were assigned in a 1:1 ratio to usual care or usual care plus colchicine. Colchicine was administered orally in a loading dose of 1.5 mg immediately after randomization, followed by 0.5 mg orally within 2 hours of the initial dose and 0.5 mg orally twice a day for 14 days or discharge, whichever occurred first. MAIN OUTCOMES AND MEASURES The first coprimary outcome was the composite of a new requirement for mechanical ventilation or death evaluated at 28 days. The second coprimary outcome was death at 28 days. RESULTS A total of 1279 hospitalized patients (mean [SD] age, 61.8 [14.6] years; 449 [35.1%] women and 830 [64.9%] men) were randomized, including 639 patients in the usual care group and 640 patients in the colchicine group. Corticosteroids were used in 1171 patients (91.5%). The coprimary outcome of mechanical ventilation or 28-day death occurred in 160 patients (25.0%) in the colchicine group and 184 patients (28.8%) in the usual care group (hazard ratio [HR], 0.83; 95% CI, 0.67-1.02; P = .08). The second coprimary outcome, 28-day death, occurred in 131 patients (20.5%) in the colchicine group and 142 patients (22.2%) in the usual care group (HR, 0.88; 95% CI, 0.70-1.12). Diarrhea was the most frequent adverse effect of colchicine, reported in 68 patients (11.3%).
Conflict of Interest Disclosures: Dr Orlandini reported receiving grants from Population Health Research Institution during the conduct of the study. Dr Lamelas reported receiving personal fees from Boston Scientific, Medtronic, Edwards, and Meril outside the submitted work. Dr Miró reported receiving grants from Angelini, Contrafect, Gilead Sciences, MSD, Novartis, Pfizer, and ViiV Healthcare and personal fees from Gilead Sciences, Jansen, Lysovant, Medtronic, MSD, Novartis, and Pfizer outside the submitted work. Dr Eikelboom reported receiving grants and personal fees from Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Janssen, and Sanofi-Aventis and personal fees from Daiichi-Sankyo, Eli-Lilly, and Servier during the conduct of the study. Funding/Support: The Population Health Research Institute contributed fees to the investigators. Fundacion ECLA funded all other aspects of the trial. Role of the Funder/Sponsor: Fundacion ECLA was responsible for the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Administrative, Orlandini, Castellana, Caccavo, Corral et al., None
Gaba, Bhatt, The COVID-19 pandemic: a catalyst to improve clinical trials, Nat Rev Cardiol, doi:10.1038/s41569-020-00439-7
Ghosn, Chaimani, Evrenoglou, Interleukin-6 blocking agents for treating COVID-19: a living systematic review, Cochrane Database Syst Rev, doi:10.1002/14651858.CD013881
Harris, Taylor, Thielke, Payne, Gonzalez et al., Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, doi:10.1016/j.jbi.2008.08.010
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2021436
Medical, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, JAMA, doi:
Moore, June, Cytokine release syndrome in severe COVID-19, Science, doi:10.1126/science.abb8925
Nidorf, Fiolet, Mosterd, LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease, N Engl J Med, doi:10.1056/NEJMoa2021372
Orlandini, Castellana, Domínguez, Scarafia, Eikelboom, Obtained funding: Orlandini
Pan, Peto, Henao-Restrepo, WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19-interim WHO solidarity trial results, N Engl J Med, doi:10.1056/NEJMoa2023184
Reyes, Hu, Teperman, Anti-inflammatory therapy for COVID-19 infection: the case for colchicine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219174
Richardson, Hirsch, Narasimhan, the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA, doi:
Tardif, Bouabdallaoui, Allier, Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv, doi:10.1101/2021.01.26.21250494
Tardif, Kouz, Waters, Efficacy and safety of low-dose colchicine after myocardial infarction, N Engl J Med, doi:10.1056/NEJMoa1912388
Yusuf, Collins, Peto, Why do we need some large, simple randomized trials?, Stat Med, doi:10.1002/sim.4780030421
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop